重组戊型肝炎疫苗在成人中的长期效力:一项随机双盲安慰剂对照3期试验的10年结果
该研究为在中国东台县开展的随机双盲安慰剂对照3期试验的扩展研究,112604名16-65岁健康成人按1:1随机接受三剂戊型肝炎疫苗或安慰剂肌内注射。10年随访期间疫苗组戊型肝炎发病率为0.2/万人年,安慰剂组为1.4/万人年,改良意向治疗分析疫苗效力为83.1%(95%CI 69.4-91.4),符合方案分析为86.6%(95%CI 73.0-94.1)。
要点
- 10年随访中疫苗组戊型肝炎发病率0.2/万人年,安慰剂组1.4/万人年。
- 改良意向治疗分析疫苗效力83.1%(95%CI 69.4-91.4)。
- 符合方案分析疫苗效力86.6%(95%CI 73.0-94.1)。
核心结论
- 接种该戊型肝炎疫苗可提供长达10年的持久保护,疫苗诱导的抗HEV抗体至少持续8.5年。
研究设计与样本
- 本研究为在中国江苏东台县开展的随机双盲安慰剂对照3期临床试验的扩展研究。
- 初始试验共纳入112604名16-65岁健康成人,按年龄和性别分层后以1:1比例随机分配,在第0、1、6个月肌内注射三剂戊型肝炎疫苗或安慰剂。
- 建立了覆盖整个研究区域的敏感戊型肝炎监测系统,包括205个临床哨点,并在接种后维持10年。
- 主要结局为符合方案分析中预防第三剂接种后至少30天发生的确诊戊型肝炎的疫苗效力。
- 研究期间参与者、现场研究者和实验室人员对治疗分配保持盲态;该研究注册于ClinicalTrials.gov(NCT01014845)。
主要发现
- 在2007年8月22日至2017年10月31日的10年研究期间,共识别90例戊型肝炎患者,疫苗组13例(0.2/万人年),安慰剂组77例(1.4/万人年)。
- 改良意向治疗分析疫苗效力为83.1%(95%CI 69.4-91.4),符合方案分析为86.6%(95%CI 73.0-94.1)。
- 在免疫原性持久性评估亚组中,基线血清阴性且接受三剂戊型肝炎疫苗者,Qindong地区接种者在8.5年时291人中有254人(87.3%)维持可检测抗体浓度,Anfeng地区接种者在7.5年时1740人中有1270人(73.0%)维持可检测抗体浓度。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hepatitis E virus (HEV) is a frequently overlooked causative agent of acute hepatitis. Evaluating the long-term durability of hepatitis E vaccine efficacy holds crucial importance. METHODS: This study was an extension to a randomised, double-blind, placebo-controlled, phase-3 clinical trial of the hepatitis E vaccine conducted in Dontai County, Jiangsu, China. Participants were recruited from 11 townships in Dongtai County. In the initial trial, a total of 112 604 healthy adults aged 16-65 years were enrolled, stratified according to age and sex, and randomly assigned in a 1:1 ratio to receive three doses of hepatitis E vaccine or placebo intramuscularly at month 0, month 1, and month 6. A sensitive hepatitis E surveillance system including 205 clinical sentinels, covering the entire study region, was established and maintained for 10 years after vaccination. The primary outcome was the per-protocol efficacy of hepatitis E virus vaccine to prevent confirmed hepatitis E occurring at least 30 days after administration of the third dose. Throughout the study, the participants, site investigators, and laboratory staff remained blinded to the treatment assignments. This study is registered with ClinicalTrials.gov (NCT01014845). FINDINGS: During the 10-year study period from Aug 22, 2007, to Oct 31, 2017, 90 people with hepatitis E were identified; 13 in the vaccine group (0·2 per 10 000 person-years) and 77 in the placebo group (1·4 per 10 000 person-years), corresponding to a vaccine efficacy of 83·1% (95% CI 69·4-91·4) in the modified intention-to-treat analysis and 86·6% (73·0 to 94·1) in the per-protocol analysis. In the subsets of participants assessed for immunogenicity persistence, of those who were seronegative at baseline and received three doses of hepatitis E vaccine, 254 (87·3%) of 291 vaccinees in Qindong at the 8·5-year mark and 1270 (73·0%) of 1740 vaccinees in Anfeng at the 7·5-year mark maintained detectable concentrations of antibodies. INTERPRETATION: Immunisation with this hepatitis E vaccine offers durable protection against hepatitis E for up to 10 years, with vaccine-induced antibodies against HEV persisting for at least 8·5 years. FUNDING: National Natural Science Foundation of China, Fujian Provincial Natural Science Foundation, Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences, and the Fundamental Research Funds for the Central Universities.
引用
- Huang S, Zhang X, Su Y, et al. Long-term efficacy of a recombinant hepatitis E vaccine in adults: 10-year results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2024. PMID: 38387470. doi:10.1016/S0140-6736(23)02234-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。